Document Detail


Phase I clinical trial of MAF containing preparation of RPMI-1788 B-cell human lymphoblastoid lymphokine in advanced cancer patients.
MedLine Citation:
PMID:  3537547     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We report a summary of a Phase I clinical trial of the partially purified MAF-containing supernatant of RPMI-1788 human B-cell lymphoblastoid lymphokine conducted in 39 patients with advanced cancer. The trial was conducted in four parts: two subcutaneous and two intravenous routes and schedules of administration. Dose limiting toxicity in the subcutaneous trials was volume dependent. The intravenous trial was remarkably well tolerated so that the maximum tolerable dose exceeded expectations. The study demonstrated modification of the immune system including an increase in skin test reactivity, an increase in absolute lymphocyte counts, alteration in the monoclonal lymphocyte antibody markers, and an increase in MAF activity. Toxicity in the intravenous trial was limited to transient febrile reactions that were ameliorated by increasing the infusion time. Three objective tumor responses were observed.
Authors:
R D Reynolds; A Khojasteh; B W Papermaster; J E McEntire
Related Documents :
10092957 - Clinical pharmacokinetics of docetaxel.
6365497 - Important considerations for the clinical evaluation of drugs: appropriate dosing regim...
11443627 - Gemcitabine modulation of alkylator therapy: a phase i trial of escalating gemcitabine ...
19065567 - Phase i study of su5416, a small molecule inhibitor of the vascular endothelial growth ...
10879657 - Action of ethanol on different skull and brain parameters in the chick embryo.
21338817 - Metabolism of 2-hydroxy-4-(methylthio)butanoate (hmtba) in lactating dairy cows.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Lymphokine research     Volume:  5 Suppl 1     ISSN:  0277-6766     ISO Abbreviation:  Lymphokine Res.     Publication Date:  1986  
Date Detail:
Created Date:  1987-01-02     Completed Date:  1987-01-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8308208     Medline TA:  Lymphokine Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S165-70     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
B-Lymphocytes / immunology
Drug Evaluation
Female
Fever / chemically induced
Humans
Immunotherapy
Infusions, Intravenous
Injections, Subcutaneous
Lymphokines / administration & dosage,  adverse effects,  therapeutic use*
Macrophage-Activating Factors
Male
Neoplasms / immunology,  therapy*
Chemical
Reg. No./Substance:
0/Lymphokines; 0/Macrophage-Activating Factors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent ...
Next Document:  Analysis of IL-2 producing subsets of human lymphocytes.